Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines

British Journal of Cancer

Volumn 81, Issue 8, 1999, Pages 1285-1293

  Te Poele, R H ^a,b   Joel, S P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Apoptosis; Cell cycle; Colon adenocarcinoma cell lines; p53; Schedule; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CELL DNA; DNA TOPOISOMERASE; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032731528     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6694370     Document Type: Article

References (32)

1. Armand JP (1996) CPT-II: clinical experience in phase I studies. Semin Oncol 23: 27-33
2. Bendixen C, Thomsen B, Alsner J and Westergaard O (1990) Camptothecin-stabilized topoisomerase I DNA adducts cause premature termination of transcription. Biochemistry 29: 5613-5619
3. Bissery MC, Vrignaud P, Lavelle F and Chabot GG (1996) Experimental antitumour activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-II) in mice. Anticancer Drugs 7: 437-460
4. Burris HAd, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG and Von Hoff DD (1992) Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84: 1816-1820
5. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F and Mathieu-Boue A (1996) Pharmacokinetics and pharmocodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14: 2688-2695
6. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47: 943-946
7. Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cole C, Engel C, Gouyette A, Mathieu-Boue A, Mahjoubi M and Clavel M (1995) Phase I and pharmacokinetic study of irinotecan (CPT-II) administered daily for three consecutive days every three weeks in patients with advanced solid tumors [see comments]. Ann Oncol 6: 133-140
8. Darzynkiewicz Z, Li X and Gong J (1994) Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol 41: 15-38
9. Del Bino G, Skierski JS and Darzynkiewicz Z (1990) Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Res 50: 5746-5750
10. Di Leonardo A, Linke SP, Clarkin K and Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540-2551
11. Dubrez L, Goldwasser F, Genne P, Pommier Y and Solary E (1995) The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 9: 1013-1024
12. Fukuoka M and Masuda N (1994) Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 34: S105-S111
13. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW and Pommier Y (1996) Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56: 4430-4437
14. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ and et al (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553-559
15. Horiguchi T, Hayashi K, Tsubotani S, Tinuma S, Harada S and Tanida S (1994) New naphthacenecarboxamide antibiotics, TAN-1518 A and B, have inhibitory activity against mammalian DNA topoisomerase I. J Antibiotics 47: 545-556
16. Houghton PJ, Cheshire PJ, Hallman JDn, Lutz L, Friedman HS, Danks MK and Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice hearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403
17. Hsiang YH and Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48. 1722-1726
18. Hsiang YH, Hertzberg R, Hecht S and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878
19. Hsiang YH, Lihou MG and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082
20. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T and Matsumoto K (1991) Antitumor activity of a camptothecin derivative, CPT-II, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192-198
21. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. [Review]. Annu Rev Biochem 58: 351-375
22. Muggia FM, Creaven PJ, Hansen HII, Cohen MH and Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemotherapy Reports - Part I 56: 515-521
23. Nelson WG and Kastan MB (1994) DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823
24. Pantazis P, Mendoza JT, Early JA, Kozielski AJ, Natelson EA and Giovanella BC (1993) 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myclomonocytic leukemia lines in vitro. Eur J Haematol 50: 81-89
25. Phillips PC, Janss A and Kaufmann SH (1994) Topoisomerase I inhibitor schedule dependent activity and determinants of cytotoxicity in human brain tumors cell lines. Proc Annu Meet Am Assoc Cancer Res 35
26. Poot M, Hiller KH, Heimpel S and Hoehn H (1995) Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity. Exp Cell Res 218: 326-330
27. Rolley N, Butcher S and Milner J (1995) Specific DNA binding by different classes of human p53 mutants. Oncogene 11: 763-770
28. Rubin F, Pantazis P, Bharti A, Toppmeyer D, Giovanella B and Kufe D (1994) Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem 269: 2433-2439
29. Stichenmyer WJ, Rowinsky EK, Grochow LB, Kaufman SH and Donehauwer RC (1994) Camptothecin analogues: studies from The Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34: S53-S57
30. Solary E, Dubrez L, Eymin B, Bertrand R and Pommier Y (1996) [Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors]. Bull Cancer (Paris) 83: 205-212
31. Von Hoff D, Burris HR, Eckardt J, Rothenberg M, Fields SM, Chen SF and Kuhn JG (1994) Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol
32. Wang JC (1985) DNA topoisomerase. Annu Rev Biochem 54: 665-697